View Clinical Trial (Medical Research Study)
Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations
| City: |
|
Detroit |
| State: |
|
Michigan |
| Zip Code: |
|
48235 |
| Conditions: |
|
Malignant Mesothelioma - Pulmonary Complications |
| Purpose: |
|
RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to
asbestos or vermiculite in the laboratory may help doctors learn more about changes that may
occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in
patients exposed to asbestos or vermiculite.
|
| Study Summary: |
|
OBJECTIVES:
- Identify patients with known asbestos exposure at early stages of disease development
(i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural
mesothelioma).
- Determine the expression levels of tumor-associated proteins in these patients.
- Analyze samples of serum and pleural effusions obtained from these patients.
- Determine the proteomic profile of samples obtained from these patients.
- Determine the molecular mechanisms associated with the regulation of the extracellular
matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix
metalloproteins) involved in disease onset and progression.
OUTLINE: This is a multicenter study.
Patients undergo collection of body cavity fluid, including pleural effusion, and blood.
Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available,
are analyzed for proteomic profile, gene expression profile, and tumor-associated protein
expression levels.
PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Exposure to vermiculite or asbestos insulation
- Symptomatic or nonsymptomatic exposure-related disease
- Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
|
| NCT ID: |
|
NCT00897247 |
| Primary Contact: |
|
Study Chair
Anil Wali, PhD
Barbara Ann Karmanos Cancer Institute
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Detroit, Michigan 48235
United States
Naimei Tang
Phone: 313-966-3300
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|